ASHP, Partners Defend Clinicians' Ability to Provide Evidence-Based Off-Label Care

ASHP and more than a dozen medical professional societies and patient advocacy organizations filed amicus briefs urging courts to reject the U.S. Department of Justice’s (DOJ) argument that off-label use of a medication amounts to introducing a misbranded drug into the supply chain in violation of the Federal Food, Drug, and Cosmetic Act.